Significance of the Prognostic Nutritional Index in Patients with Glioblastoma: A Retrospective Study

Xing-Wang Zhou,Hui Dong,Yuan Yang,Jie-Wen Luo,Xiang Wang,Yan-Hui Liu,Qing Mao

DOI: https://doi.org/10.1016/j.clineuro.2016.10.014

IF: 1.885

2016-01-01

Clinical Neurology and Neurosurgery

Abstract:Objective: Accumulating evidence demonstrates that prognostic nutritional index(PNI) is linked to the clinical outcome of patients with malignant tumors, but few studies had investigated the clinical significance of PNI in glioblastoma multiforme(GBM). This study aimed to clarify the association between PNI and the clinical outcome of patients with GBM.Methods: The clinical data of 84 patients with GBM were retrospectively analyzed. PNI was calculated from the following formula: 10 x serum albumin (OR) + 0.005 x total lymphocyte count (per mm(3)). X-tile software was used to determine the cut-off of PNI and other hematological parameters. GBM patients were dichotomized as two groups based on the PNI cut-off.Results: The optimal PNI cut-off level was 44.4. There were 14 patients with a PNI <44.4 and 70 patients with a PNI >= 44.4. The results showed that PNI score was associated with gender, serum albumin, and hemoglobin level. Univariate analysis suggested that age, extent of resection, adjuvant treatment, platelet count and PNI score were predictors of overall survival in patients with GBM. The 1- and 2-survival rates of patients with a PNI <44.4 were 28.60 and 0%, respectively, while the corresponding values for patients with a PNI >= 44.4 were 52.90 and 5.70%, respectively. Based on multivariate analysis, a PNI >= 44.4 (HR:0.479, 95% CI:0.235-0.975,p = 0.042) remained an independent prognostic indicator for a favorable outcome of patients with GBM. Furthermore, patients with a PNI >= 44.4 may have a better efficacy of adjuvant treatment than patients with a PNI <44.4 (HR:0.259, 95% CI:0.096-0.700, p = 0.008).Conclusion: A PNI > 44.4 was an independent prognostic parameter of overall survival in patients with GBM and the efficacy of adjuvant treatment. Interventions aimed at correcting the nutritional and immune status of patients with GBM may, therefore, promote the effectiveness of adjuvant treatment and improve the survival outcomes. (C) 2016 Elsevier B.V. All rights reserved.